Champoux Jennifer sold 2,176 shares of Monte Rosa Therapeutics, Inc. at $19.00 for −$41.3k on May 22, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Chief Operating Officer
Chief Operating Officer
Filed May 26, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$41,344Shares × reported price
Shares traded
2,176Common Stock
Price per share
$19.00Reported price. Read footnotes for ranges.
% of reported position traded
3.37%This security and ownership context
Holdings after
62,371Direct
Trade date
May 22, 2026Sell
Filed
May 26, 2026, 4:05 PM ET4-day reporting delay
Accession
0001193125-26-239240Code S · Transaction 385125
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 64,547 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
May 22, 2026Option exercise2,176$0.00$0Trade 385126
May 22, 2026Option exercise2,176$3.98$8,660.48Trade 385124
3 transaction rows in this filing. Joint filers share the same rows.

GLUE price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
GLUE · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +9.3%1w ago −5.5%1d ago −1.7%
Returns since7d −7.6%30d +13%90d −28%180d1y

Footnotes in full

F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026. F2: 25% of this option vested on May 28, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.